The myasthenia gravis treatment market is anticipated to grow at a CAGR of 7.14% from US$1.973 billion in 2025 to US$2.785 ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile in adult patients with generalized myasthenia gravis, offering a promising ...

Those who suffer myasthenia gravis experience muscle weakness that can affect the muscles we use to blink, smile and move our bodies. Researchers used a cutting-edge imaging technique to uncover new ...

gMG is different from ocular myasthenia gravis, which only affects the eye muscles. “Anti-acetylcholine receptor (AChR) antibody-positive” means your immune system makes antibodies that block ...

This review aims to discuss recent and previous findings on the role of complement in AChR-Ab+ MG pathology, including its interaction with pathogenic antibodies and mechanisms beyond the classical ...